A Phase 1 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GS-1206 in Adults With Solid Tumors
Gilead Sciences
Summary
The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * All individuals must have a tumor with protocol-specified mutation as determined by local health-authority approved test. * For Part A (including backfill cohorts): Individuals with histologically confirmed advanced or metastatic solid tumors who have progressed following treatment in the advanced or metastatic setting known to confer clinical benefit, unless the individual refused, is intolerant to, or is not eligible for standard-of-care (SOC) treatment. * For Part B dose expansion, individuals with protocol-specified tumor types will be enrolled. Key Exclusion Cr…
Interventions
- DrugGS-1206
Administered Orally
Locations (3)
- NEXT Oncology DallasAustin, Texas
- NEXT OncologySan Antonio, Texas
- START San Antonio, LLCSan Antonio, Texas